GenFleet Therapeutics (Shanghai) Inc. will hold its 2025 Annual General Meeting on 11 May 2026 at 10:00 a.m. in Shanghai. Shareholders will vote on 11 resolutions, covering routine reporting items, revisions to corporate governance rules, and two capital-management mandates.
Key items up for approval:
1. Statutory Reports and Financials • 2025 Board Report, audited consolidated financial statements, and annual report.
2. Board and Auditor Matters • Directors’ remuneration packages for 2025 and 2026. • Re-appointment of Ernst & Young as external auditor for 2026, with the Board authorised to set fees.
3. Governance Framework Updates • Amendments to working rules for independent non-executive directors. • Revisions to the related-party transaction management system. • Amendments to the Rules of Procedure for Shareholders’ Meetings and the Board of Directors.
4. Special Resolutions on Capital Management • Share buy-back mandate: authority to repurchase up to 10% of total issued shares (excluding treasury shares) on the Stock Exchange during the mandate period, defined as the earlier of the next AGM, 12 months, or revocation by shareholders. • General issuance mandate: authority to allot, issue or deal with new shares—including sale or transfer of treasury shares—up to 20% of total issued share capital (excluding treasury shares). The Board would be empowered to amend the Articles of Association to reflect any resulting changes in share capital and to handle all regulatory filings.
Meeting logistics:
• Record date: 11 May 2026. • Share register closure: 6–11 May 2026 (both days inclusive). H-shareholders must lodge transfer documents by 4:30 p.m., 5 May 2026 with Computershare Hong Kong Investor Services to qualify for attendance and voting. • Proxies: Shareholders may appoint one or more proxies; forms must be deposited at designated locations no later than 24 hours before the meeting.
The meeting is expected to conclude within half a day, and attendees will bear their own travel and accommodation costs.
Comments